Meeting
2024 ASCO Annual Meeting
The design, preclinical study and phase I dose escalation plan of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment.
Authors
Shanshan Jin
Hangzhou HighField Biopharmaceuticals Corporation, Hangzhou, China
Shanshan Jin , Xiaochen Zhang , Yunlu Jia , Yongchao Dai , Fengwei Xu , Yongfeng Huang , Xun Wang , Hailong Wu , Yu Shao , Jinfeng Long , Anjie Zheng , Yuhong Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Clinical Trial Registration Number
NCT 05861895
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 3035)
DOI
10.1200/JCO.2024.42.16_suppl.3035
Abstract #
3035
Poster Bd #
180
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
![Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC).](https://d201v5jt9ylckg.cloudfront.net/288/14358/211355/211355_A1369_poster_pv.jpg)
Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC).
First Author: Fabrice Andre
Poster
2020 Gastrointestinal Cancers Symposium
MT-5111: A novel HER2 targeting engineered toxin body in clinical development.
First Author: Roger J. Waltzman
Poster
2024 ASCO Annual Meeting
An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, and pharmacokinetics of VIP236 monotherapy in patients with advanced cancer.
First Author: Andrae L. Vandross
Poster
2023 ASCO Annual Meeting
Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.
First Author: John Heymach